Dynamics of tumor hypoxia assessed by F-18-FAZA PET/CT in head and neck and lung cancer patients during chemoradiation: Possible implications for radiotherapy treatment planning strategiesBollineni, V. R., Koole, M. J. B., Pruim, J., Brouwer, C. L., Wiegman, E. M., Groen, H. J. M., Vlasman, R., Halmos, G. B., Oosting, S. F., Langendijk, J. A., Widder, J. & Steenbakkers, R. J. H. M., Nov-2014, In : Radiotherapy and Oncology. 113, 2, p. 198-203 6 p.
Research output: Contribution to journal › Article › Academic › peer-review
INTRODUCTION: To define the optimal time point for the integration of hypoxia (18)F-FAZA-PET/CT information into radiotherapy treatment planning to benefit from hypoxia modification or dose escalation treatment. Therefore, we performed a prospective cohort study, using serial hypoxic imaging ((18)F-FAZA-PET/CT) prior to and at several time-points during (chemo)radiotherapy (CHRT) in six head and neck squamous cell (HNSCC) and six non-small cell lung cancer (NSCLC) patients.
METHODS: The spatio-temporal dynamics of tumor hypoxia and fractional hypoxic volumes (FHV) were evaluated using a voxel-by-voxel analysis based on a (18)F-FAZA-T/B ratio of 1.4 at four time points in HNSCC patients, at baseline (FAZA-BL), at week one (FAZA-W1), two (FAZA-W2), and four (FAZA-W4) during CHRT and at three time points in NSCLC patients (baseline; W2, W4).
RESULTS: Ten out of twelve patients showed a substantial pre-treatment tumor hypoxia representing a FHV⩾1.4 assessed by (18)F-FAZA-PET/CT. The median FHV was 38% (FAZA-BL), 15% (FAZA-W1), 17% (FAZA-W2) and 1.5% (FAZA-W4) in HNSCC patients, and 34% (FAZA-BL), 26% (FAZA-W2) and 26% (FAZA-W4) in NSCLC patients, respectively. Stable tumor hypoxia was observed in three HNSCC patients and two NSCLC patients at FAZA-W2. In three HNSCC patients and two NSCLC patients FHVs declined to non-detectable hypoxia levels at FAZA-W4 during CHRT, while two NSCLC patients, showed increasing FHVs.
CONCLUSION: Our results indicate that, instead of using the FAZA-BL scan as the basis for the dose escalation, FAZA-W2 of CHRT is most suitable and might provide a more reliable basis for the integration of (18)F-FAZA-PET/CT information into radiotherapy treatment planning for hypoxia-directed dose escalation strategies.
|Number of pages||6|
|Journal||Radiotherapy and Oncology|
|Publication status||Published - Nov-2014|
- Tumor hypoxia, F-18-FAZA-PET/CT, Head and neck tumors, Non-small-cell lung cancer, FHV, POSITRON-EMISSION-TOMOGRAPHY, SURVIVAL, TRIAL